Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Inflammation
Published in: Journal of Inflammation 1/2006

Open Access 01-12-2006 | Short Report

Heparan sulfate proteoglycan-dependent neutrophil chemotaxis toward PR-39 cathelicidin

Authors: Angela Djanani, Birgit Mosheimer, Nicole C Kaneider, Christopher R Ross, Giovanni Ricevuti, Josef R Patsch, Christian J Wiedermann

Published in: Journal of Inflammation | Issue 1/2006

Login to get access

Abstract

Cathelicidins are mammalian proteins containing a C-terminal cationic antimicrobial domain. Porcine PR-39 cathelicidin affects leukocyte biology. Mechanisms of action may involve alteration of heparan sulfate proteoglycan-dependent functions in inflammatory cells. It was tested whether PR-39 affects human neutrophil migration and if such effects involve heparan sulphate proteoglycans. Neutrophils were from forearm venous blood of healthy donors. Migration was tested in modified Boyden chamber assays. Involvement of heparan sulfate proteoglycans was tested by their chemical modification and by the use of specific antibodies. PR-39 induced migration in neutrophils in a concentration dependent manner. Modification of heparan sulfate proteoglycans with sodium chlorate inhibited migration whereas chemotaxis toward the chemoattractant formyl-Met-Leu-Phe was not affected. Removal of heparan sulfates or chondroitin sulfates from the surface of neutrophils by heparinase or chondroitinase inhibited migration toward PR-39. In conclusion, antimicrobial PR-39 stimulates human neutrophil chemotaxis in a heparan sulfate proteoglycan-dependent manner. Involvment of syndecans is likely as both heparinase and chondroitinase were abrogating. Data suggest active participation of heparan sulfate proteoglycans of neutrophils in cathelicidin peptide-mediated regulation of the antimicrobial host defense.
Appendix
Available only for authorised users
Literature
1.
Lehrer RI, Ganz T: Defensins of vertebrate animals. Curr Opin Immunol. 2002, 14: 96-102. 10.1016/S0952-7915(01)00303-X.PubMedCrossRef
2.
Lehrer RI, Ganz T: Cathelicidins: a family of endogenous antimicrobial peptides. Curr Opin Hematol. 2002, 9: 18-22. 10.1097/00062752-200201000-00004.PubMedCrossRef
3.
Zaiou M, Gallo RL: Cathelicidins, essential gene-encoded mammalian antibiotics. J Mol Med. 2002, 80: 549-61. 10.1007/s00109-002-0350-6.PubMedCrossRef
4.
Zanetti M, Gennaro R, Romeo D: Cathelicidins: a novel protein family with a common proregion and a variable C-terminal antimicrobial domain. FEBS Lett. 1995, 374: 1-5. 10.1016/0014-5793(95)01050-O.PubMedCrossRef
5.
Zanetti M, Del Sal G, Storici P, Schneider C, Romeo D: The cDNA of the neutrophil antibiotic Bac5 predicts a pro-sequence homologous to a cysteine proteinase inhibitor that is common to other neutrophil antibiotics. J Biol Chem. 1993, 268: 522-6.PubMed
6.
Bagella L, Scocchi M, Zanetti M: cDNA sequences of three sheep myeloid cathelicidins. FEBS Lett. 1995, 376: 225-8. 10.1016/0014-5793(95)01285-3.PubMedCrossRef
7.
Gallo RL, Kim KJ, Bernfield M, Kozak CA, Zanetti M, Merluzzi L, Gennaro R: Identification of CRAMP, a cathelin-related antimicrobial peptide expressed in the embryonic and adult mouse. J Biol Chem. 1977, 272: 13088-93. 10.1074/jbc.272.20.13088.CrossRef
8.
Agerberth B, Gunne H, Odeberg J, Kogner P, Boman HG, Gudmundsson GH: FALL-39, a putative human peptide antibiotic, is cysteine-free and expressed in bone marrow and testis. Proc Natl Acad Sci USA. 1995, 92: 195-9. 10.1073/pnas.92.1.195.PubMedPubMedCentralCrossRef
9.
Storici P, Scocchi M, Tossi A, Gennaro R, Zanetti M: Chemical synthesis and biological activity of a novel antibacterial peptide deduced from a pig myeloid cDNA. FEBS Lett. 1994, 337: 303-7. 10.1016/0014-5793(94)80214-9.PubMedCrossRef
10.
Tossi A, Scocchi M, Zanetti M, Storici P, Gennaro R: PMAP-37, a novel antibacterial peptide from pig myeloid cells. cDNA cloning, chemical synthesis and activity. Eur J Biochem. 1995, 228: 941-6. 10.1111/j.1432-1033.1995.tb20344.x.PubMedCrossRef
11.
Zanetti M, Litteri L, Gennaro R, Horstmann H, Romeo D: Bactenecins, defense polypeptides of bovine neutrophils, are generated from precursor molecules stored in the large granules. J Cell Biol. 1990, 111: 1363-71. 10.1083/jcb.111.4.1363.PubMedCrossRef
12.
Gallo RL, Ono M, Povsic T, Page C, Eriksson E, Klagsbrun M, Bernfield M: Syndecans, cell surface heparan sulfate proteoglycans, are induced by a proline-rich antimicrobial peptide from wounds. Proc Natl Acad Sci USA. 1994, 91: 11035-9. 10.1073/pnas.91.23.11035.PubMedPubMedCentralCrossRef
13.
Frohm NM, Sandstedt B, Sorensen O, Weber G, Borregaard N, Stahle-Backdahl M: The human cationic antimicrobial protein (hCAP18), a peptide antibiotic, is widely expressed in human squamous epithelia and colocalizes with interleukin-6. Infect Immun. 1999, 67: 2561-6.
14.
Sorensen O, Arnljots K, Cowland JB, Bainton DF, Borregaard N: The human antibacterial cathelicidin, hCAP-18, is synthesized in myelocytes and metamyelocytes and localized to specific granules in neutrophils. Blood. 1997, 90: 2796-803.PubMed
15.
Agerberth B, Lee JY, Bergman T, Carlquist M, Boman HG, Mutt V, Jornvall H: Amino acid sequence of PR-39. Isolation from pig intestine of a new member of the family of proline-arginine-rich antibacterial peptides. Eur J Biochem. 1991, 202: 849-54. 10.1111/j.1432-1033.1991.tb16442.x.PubMedCrossRef
16.
Shi J, Ross CR, Chengappa MM, Blecha F: Identification of a proline-arginine-rich antibacterial peptide from neutrophils that is analogous to PR-39, an antibacterial peptide from the small intestine. J Leukoc Biol. 1994, 56: 807-11.PubMed
17.
Shi J, Ross CR, Chengappa MM, Sylte MJ, McVey DS, Blecha F: Antibacterial activity of a synthetic peptide (PR-26) derived from PR-39, a proline-arginine-rich neutrophil antimicrobial peptide. Antimicrob Agents Chemother. 1996, 40: 115-21.PubMedPubMedCentral
18.
Boman HG, Agerberth B, Boman A: Mechanisms of action on Escherichia coli of cecropin P1 and PR-39, two antibacterial peptides from pig intestine. Infect Immun. 1993, 61: 2978-84.PubMedPubMedCentral
19.
Ohtake T, Fujimoto Y, Ikuta K, Saito H, Ohhira M, Ono M, Kohgo Y: Proline-rich antimicrobial peptide, PR-39 gene transduction altered invasive activity and actin structure in human hepatocellular carcinoma cells. Br J Cancer. 1999, 8: 393-403. 10.1038/sj.bjc.6690707.CrossRef
20.
Li J, Post M, Volk R, Gao Y, Li M, Metais C, Sato K, Tsai J, Aird W, Rosenberg RD, Hampton TG, Sellke F, Carmeliet P, Simons M: PR39, a peptide regulator of angiogenesis. Nat Med. 2000, 6: 49-55. 10.1038/71527.PubMedCrossRef
21.
Koenig A, Norgard-Sumnicht K, Linhardt R, Varki A: Differential interactions of heparin and heparan sulfate glycosaminoglycans with the selectins. Implications for the use of unfractionated and low molecular weight heparins as therapeutic agents. J Clin Invest. 1998, 101: 877-89.PubMedPubMedCentralCrossRef
22.
Parmley RT, Hurst RE, Takagi M, Spicer SS, Austin RL: Glycosaminoglycans in human neutrophils and leukemic myeloblasts: ultrastructural, cytochemical, immunologic, and biochemical characterization. Blood. 1983, 61: 257-66.PubMed
23.
Yeaman C, Rapraeger AC: Membrane-anchored proteoglycans of mouse macrophages: P388D1 cells express a syndecan-4-like heparan sulfate proteoglycan and a distinct chondroitin sulfate form. J Cell Physiol. 1993, 157: 413-25. 10.1002/jcp.1041570226.PubMedCrossRef
24.
Yeaman C, Rapraeger AC: Post-transcriptional regulation of syndecan-1 expression by cAMP in peritoneal macrophages. J Cell Biol. 1993, 122: 941-50. 10.1083/jcb.122.4.941.PubMedCrossRef
25.
Huang HJ, Ross CR, Blecha F: Chemoattractant properties of PR-39, a neutrophil antibacterial peptide. J Leukoc Biol. 1997, 61: 624-9.PubMed
26.
Dunzendorfer S, Kaneider N, Rabensteiner A, Meierhofer C, Reinisch C, Romisch J, Wiedermann CJ: Cell-surface heparan sulfate proteoglycan-mediated regulation of human neutrophil migration by the serpin antithrombin III. Blood. 2001, 97: 1079-85. 10.1182/blood.V97.4.1079.PubMedCrossRef
27.
Mertens G, Cassiman JJ, Van den Berghe H, Vermylen J, David G: Cell surface heparan sulfate proteoglycans from human vascular endothelial cells. Core protein characterization and antithrombin III binding properties. J Biol Chem. 1992, 267: 20435-43.PubMed
28.
James PE, Madhani M, Ross C, Klei L, Barchowsky A, Swartz HM: Tissue hypoxia during bacterial sepsis is attenuated by PR-39, an antibacterial peptide. Adv Exp Med Biol. 2003, 530: 645-52.PubMedCrossRef
29.
Madhani M, Barchowsky A, Klei L, Ross CR, Jackson SK, Swartz HM, James PE: Antibacterial peptide PR-39 affects local nitric oxide and preserves tissue oxygenation in the liver during septic shock. Biochim Biophys Acta. 2002, 1588: 232-40.PubMedCrossRef
30.
De Y, Chen Q, Schmidt AP, Anderson GM, Wang JM, Wooters J, Oppenheim JJ, Chertov O: LL-37, the neutrophil granule- and epithelial cell-derived cathelicidin, utilizes formyl peptide receptor-like 1 (FPRL1) as a receptor to chemoattract human peripheral blood neutrophils, monocytes, and T cells. J Exp Med. 2000, 192: 1069-74. 10.1084/jem.192.7.1069.CrossRef
31.
Niyonsaba F, Iwabuchi K, Someya A, Hirata M, Matsuda H, Ogawa H, Nagaoka I: A cathelicidin family of human antibacterial peptide LL-37 induces mast cell chemotaxis. Immunology. 2000, 106: 20-6. 10.1046/j.1365-2567.2002.01398.x.CrossRef
32.
Kaneider NC, Egger P, Dunzendorfer S, Wiedermann CJ: Syndecan-4 as antithrombin receptor of human neutrophils. Biochem Biophys Res Commun. 2001, 287: 42-6. 10.1006/bbrc.2001.5534.PubMedCrossRef
33.
Cardin AD, Weintraub HJ: Molecular modeling of protein-glycosaminoglycan interactions. Arteriosclerosis. 1989, 9: 21-32.PubMedCrossRef
34.
Andersson E, Rydengard V, Sonesson A, Morgelin M, Bjorck L, Schmidtchen A: Antimicrobial activities of heparin-binding peptides. Eur J Biochem. 2004, 271: 1219-26. 10.1111/j.1432-1033.2004.04035.x.PubMedCrossRef
35.
Bernfield M, Gotte M, Park PW, Reizes O, Fitzgerald ML, Lincecum J, Zako M: Functions of cell surface heparan sulfate proteoglycans. Annu Rev Biochem. 1999, 68: 729-77. 10.1146/annurev.biochem.68.1.729.PubMedCrossRef
36.
Wadstrom T, Ljungh A: Glycosaminoglycan-binding microbial proteins in tissue adhesion and invasion: key events in microbial pathogenicity. J Med Microbiol. 1999, 48: 223-33.PubMedCrossRef
37.
Kjellen L, Lindahl U: Proteoglycans: structures and interactions. Annu Rev Biochem. 1991, 60: 443-75. 10.1146/annurev.bi.60.070191.002303.PubMedCrossRef
38.
Bernfield M, Kokenyesi R, Kato M, Hinkes MT, Spring J, Gallo RL, Lose EJ: Biology of the syndecans: a family of transmembrane heparan sulfate proteoglycans. Annu Rev Cell Biol. 1992, 8: 365-93. 10.1146/annurev.cb.08.110192.002053.PubMedCrossRef
39.
Chan YR, Gallo RL: PR-39, a syndecan-inducing antimicrobial peptide, binds and affects p130(Cas). J Biol Chem. 1998, 273: 28978-85. 10.1074/jbc.273.44.28978.PubMedCrossRef
40.
Honda H, Nakamoto T, Sakai R, Hirai H: p130(Cas), an assembling molecule of actin filaments, promotes cell movement, cell migration, and cell spreading in fibroblasts. Biochem Biophys Res Commun. 1999, 262: 25-30. 10.1006/bbrc.1999.1162.PubMedCrossRef
41.
Cary LA, Han DC, Polte TR, Hanks SK, Guan JL: Identification of p130Cas as a mediator of focal adhesion kinase-promoted cell migration. J Cell Biol. 1998, 140: 211-21. 10.1083/jcb.140.1.211.PubMedPubMedCentralCrossRef
42.
Wilcox-Adelman SA, Denhez F, Goetinck PF: Syndecan-4 modulates focal adhesion kinase phosphorylation. J Biol Chem. 2002, 277: 32970-7. 10.1074/jbc.M201283200.PubMedCrossRef
Metadata
Title
Heparan sulfate proteoglycan-dependent neutrophil chemotaxis toward PR-39 cathelicidin
Authors
Angela Djanani
Birgit Mosheimer
Nicole C Kaneider
Christopher R Ross
Giovanni Ricevuti
Josef R Patsch
Christian J Wiedermann
Publication date
01-12-2006
Publisher
BioMed Central
Published in
Journal of Inflammation / Issue 1/2006
Electronic ISSN: 1476-9255
DOI
https://doi.org/10.1186/1476-9255-3-14

Other articles of this Issue 1/2006

Journal of Inflammation 1/2006 Go to the issue

Research

Different roles for non-receptor tyrosine kinases in arachidonate release induced by zymosan and Staphylococcus aureus in macrophages

Research

NAC and DTT promote TGF-β1 monomer formation: demonstration of competitive binding

Research

A novel electron paramagnetic resonance-based assay for prostaglandin H synthase-1 activity

Research

The glucocorticoid RU24858 does not distinguish between transrepression and transactivation in primary human eosinophils

Research

Macrophage metalloelastase (MMP-12) deficiency does not alter bleomycin-induced pulmonary fibrosis in mice

Review

Changes in ion transport in inflammatory disease
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits